Sanyou Biopharmaceuticals Co., Ltd. has launched Clicklinks, an AI-STAL and SAI-DA powered collaborative network designed to support original drug discovery and preclinical development.
Positioned as an Innovation Hub for Original Drug Discovery, Clicklinks brings together industry partners across the biopharmaceutical value chain to enable more efficient, integrated, and scalable R&D.
Clicklinks is designed as an open, interconnected, and collaborative network ecosystem that facilitates cooperation among companies, research institutions, and individual innovators with complementary capabilities.
The platform’s objective is to accelerate the translation and application of high-value projects, technologies, and products by providing a trusted environment for collaboration. Through this approach, Clicklinks aims to empower its partners in developing next-generation therapeutics with the potential to improve patients’ quality of life and deliver transformative, potentially curative treatment solutions.
Accessible through a single web-based portal, Clicklinks integrates key stages of drug research and development across six core modules:
Core Reagents – High-quality research tools and materials.
Drug Discovery – Early-stage workflows from target validation to lead optimization.
Pharmacology & Efficacy – Comprehensive in vitro and in vivo preclinical pharmacology evaluation.
Innovative Technologies – Advanced technology platforms supporting new R&D paradigms.
Preclinical Research – Integrated PCC-IND preclinical evaluation.
Disease Frontiers – Insights into emerging disease mechanisms and therapeutic trends.
Through internal innovation and integration across upstream and downstream partners, the platform currently incorporates nearly 70 standardised and modularised technology platforms, with ongoing expansion to meet evolving R&D needs. Clicklinks is designed to provide flexible, efficient, one-stop solutions tailored to diverse development programs.
R&D activities on the platform are guided by clinical demand, with a strategic focus on nine major disease areas: oncology, metabolic diseases, autoimmune diseases, neurology, cardiovascular diseases, infectious diseases, ophthalmology, ageing-related diseases, and pet healthcare.
Building on innovative molecular foundations, Clicklinks supports a wide range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies, peptides, nucleic acids, ADCs (antibody-drug conjugates), APCs, AOCs, PDCs, POCs, and cell therapies such as CAR-T.
To enable end-to-end collaboration and global engagement, Clicklinks supports a variety of business and partnership models, including co-development of R&D platforms, establishment of NewCos, joint investments, collaborative development programs, and product and service alliances.
By fostering strategic partnerships across the industry value chain, the platform aims to promote resource sharing, complementary expertise, and collective problem-solving in response to the growing complexity of innovative drug development.
Lang Guojun, CEO of Sanyou Bio, said: “The journey of innovative drug development is long and filled with challenges. Sanyou Bio is committed to building an industry-leading, integrated drug R&D platform and, through excellence in scientific innovation and business operations, aspiring to become a global leader in innovative drug development. By working closely with partners across the industry, Sanyou Bio is dedicated to fulfilling its mission: To make it easy to develop new drugs worldwide.
“We firmly believe that Clicklinks, our Innovation Hub for Original Drug Discovery, will enable us to support our partners more consistently and effectively in achieving major breakthroughs across their drug development programs. We also look forward to collaborating with more like-minded partners to foster an open, connected, and mutually beneficial innovation ecosystem—accelerating the delivery of breakthrough therapies to patients around the world.”